Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: J Pediatr. 2017 Apr 12;186:29–33. doi: 10.1016/j.jpeds.2017.03.027

Table 3.

Incidence of Pulmonary Hypertension and Inter-Rater Reliability

Research Evaluation Incidence n(%) Clinical Evaluation Incidence n(%) Kappa*
7 Days of Age 59 (31.4) 38 (20.2) 0.54
36 Weeks PMA 28 (15.6) 32 (17.8) 0.80
*

Research and Clinical PH were determined to exist if Right Ventricular Hypertrophy,

Right Ventricular Dilation or Septal Wall Flattening were present. All PABAK values were calculated comparing Research PH and Clinical PH incidence values.